Astragaloside IV has been demonstrated to inhibit NADPH oxidase 2 (NOX2) and NOX4-mediated oxidative stress in cardiomyocytes, thereby alleviating cardiomyopathy in DOX rats [111]. Here, CYBB is linked to cardiomyopathy.